Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 4/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.45 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.44 |
| ▸ | SYK | P43405 | 5/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.35 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6469022 | 0.80 | HCAR3 (0.38) | HCAR3HCAR2SYKADRA1ATAS1R3 | |
| SCHEMBL5044822 | 0.75 | HCAR3 (0.51) | HCAR3HCAR2SIRT6ADRA1APCSK9 | |
| SCHEMBL30482996 | 0.75 | HCAR3 (0.51) | HCAR3HCAR2SIRT6ADRA1APCSK9 | |
| SCHEMBL16824379 | 0.70 | HCAR3 (0.51) | HCAR3HCAR2ADRA1ATAS1R3TAS1R1 | |
| SCHEMBL30802800 | 0.69 | NNMT (0.55) | HCAR3SIRT6ADRA1APCSK9 | |
| SCHEMBL27730675 | 0.68 | SIRT6 (0.51) | HCAR3SIRT6 | |
| SCHEMBL4253812 | 0.67 | SIRT6 (0.53) | SIRT6ADRA1AHDAC3HDAC1HDAC2 | |
| SCHEMBL6468902 | 0.67 | FYN (0.46) | HCAR3HCAR2SYKADRA1A | |
| SCHEMBL19645365 | 0.66 | SIRT6 (0.67) | SIRT6ADRA1A | |
| SCHEMBL2635320 | 0.66 | SIRT6 (0.73) | HCAR2SIRT6ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | PFIZER, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107381-A1 | 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders | APP, BACE1, SNCA | HCAR3 748/4885HCAR2 1142/4885SIRT6 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.